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Angiotens#1 H was used as a probe to study the effect of  changes in pe~fusate flow rate on the 
renal clearance parameters o f  ehlorothiazide in the isolated peJfused rat kidney. Pe~fusion studies 
were petformed in five rats with no angiotensin H present in the pelfusate and in five rats with a 
1-4 ng/min infusion of  angiotensin H into the pelfusate. Angiotensin H had a dramatic effect on 
the renal hemodynamies, resulting #~ a 43% decrease in pelfusate flow, a 16% decrease in glomeru- 
lar filtration rate (GFR), and a 45% increase in filtration fraction. Values for the fractional 
excretion o f  glucose were low and consistent, with or without angiotensin II. Although the unbound 
fraction (fu) of  ehlorothiazide was unchanged between treamlents, the renal (CLr) and the secre- 
tion clearances were reduced by about 50% in the presence of  angiotensin II; the excretion ratio 
[ER = CL~/(fu 9 GFR)] was reduced by 38% with angiotensin H present in the pelfusate. Analysis 
of  the data was complicated by the presence o f  a capacity-limited transport for renal tubular 
secretion. Transport parameters (5: SD) were obtained and the corrected intrinsic secretory clear- 
ance [(Vm,~/GFR ) /K,,,] of  chlorothiazide was 123 • 18 without angiotensin H vs. 72.8 + 30.0 with 
angiotensin 11. These results demonstrate that alterations in organ petfusion can significantly 
reduce the clearance parameters of  chlorothiazide in the rat IPK. These flow-induced changes in 
intrinsic secretoJ T transport may reflect perturbations other than that of  pelfusion flow rate alone. 
KEY WORDS: chlorothiazide; rat IPK; clearance parameters; perfusion flow rate. 
INTRODUCTION 
The kidney is a vital excretory organ in which glomerular filtration, 
proximal tubular secretion, and distal reabsorption serve to affect the irre- 
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versible removal of drugs and metabolites from the body. Despite this com- 
plex relationship, theoretical models with experimental validation have 
emerged to better understand the effect of protein binding on renal drug 
transport, and in particular, active secretion (1-3). In contrast, few quantita- 
tive data are available on the effect of changes in renal blood flow on the 
tubular secretion of drugs (4,5). As a result, the role of organ perfusion on 
renal drug extraction is conspicuously absent from the literature (6) or 
considered in a more descriptive manner (7). 
In the present study, the effect of changes in organ perfusion rate on 
the renal clearance of a highly secreted drug was investigated, and the mecha- 
nisms by which flow-induced changes might occur. Chlorothiazide was 
chosen for study because it demonstrates a net active secretion from the 
renal tubules and is eliminated solely as unchanged drug by the renal route 
(8,9). In addition, the interpretation of data from a previous study (10) 
concerning chlorothiazide transport in the isolated perfused rat kidney was 
complicated by perturbations in perfusate flow rate, the effect of which is 
not known. The isolated perfused rat kidney (rat IPK) was chosen as an 
experimental model because it allows for precise concentrations of drug and 
modulator to be presented to the kidney. Perfusate flow rate can also be 
measured directly with this technique, and experiments can be performed 
in the absence of complicating extrarenal factors (e.g., hormonal stimuli, 
peripheral tissue binding). 
METHODS 
Perfusate 
The initial perfusate volume was 100 ml. It consisted of Krebs-Henseleit 
bicarbonate (KHB) buffer containing 6.00% bovine serum albumin (BSA) 
(Fraction V; ICN ImmunoBiologicals, Lisle, IL), glucose (0.1%), and 20 L- 
amino acids (11). The BSA was previously dialyzed against an approximate 
fivefold excess of buffer without albumin (three changes over 48 hr at 4~ 
with shaking). The perfusing medium was aerated with humidified O2:CO~ 
(95:5) as it passed through a multibulb glass oxygenator and back into the 
glass reservoir; oxygenation occurred for >_1 hr prior to arterial cannulation 
and throughout the length of the experiment. Perfusate pH was monitored 
with a ~61pH meter (Beckman Instruments, Inc., Fullerton, CA) and 
adjusted, if necessary, to 7.4. 
Surgical Procedure 
The rat IPK experiments were modeled after the methods described by 
Nishiitsutsuji-Uwo et al. (12) and Bowman (13). Male Sprague-Dawley rats 
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(310-410 g) were anesthetized intraperitoneally with sodium pentobarbital 
(50 mg/kg body weight). The left superficial femoral vein was exposed and 
100 mg of mannitol and 200 units of heparin were administered. A midline 
incision was made and the major abdominal vessels were isolated. A ligature 
was passed around the right renal artery, and proximal and distal ligatures 
were placed around the mesenteric artery. The right ureter was catheterized 
with PE-10 polyethylene tubing. The right renal artery was cannulated via 
the mesenteric artery and the hemostat holding back the perfusate was 
released upon entering the renal artery. The whole kidney was then excised, 
trimmed of adhering tissue, and transferred immediately to a recirculating 
perfusion apparatus, enclosed in a temperature-controlled (37~ Plexiglas 
chamber. Perfusion pressure in the renal artery was controlled by monitoring 
the manometer and adjusting the flow-pressure valve according. A correction 
was made for the intrinsic apparatus pressure. 
Experimental Design 
Angiotensin II (AII), a biologically active octapeptide, is one of the 
most powerful constrictors of vascular smooth muscle known. As such, AII 
served as a probe to study the effect of changes in perfusate flow rate (organ 
perfusion) on the renal clearance parameters of chlorothiazide in the rat 
1PK due to its direct vasoconstriction of afferent and efferent arterioles in 
the kidney (14-16). 
Chlorothiazide (3.08 mg/ml) was dissolved in KHB buffer with the aid 
of 4 N NaOH, and [~4C]inulin (16.7/zCi/ml; specific activity, 2.0 pCi/mg; 
ICN Radiochemicals, Irvine, CA) was dissolved in distilled water. After a 
15-rain equilibration period, 3.25 ml of drug and 0.15 ml of inulin were 
introduced as a bolus into the recirculating perfusate; initial perfusate con- 
centrations of chlorothiazide were 100/~g/ml. In those experiments contain- 
ing AII (dissolved in normal saline), the peptide was introduced into the 
reservoir as a 1-4 ng/min constant-rate infusion (0.0065-0.026 ml/min), 
thereby allowing titration of the desired hemodynamic effect. An additional 
15 min were then allowed for drug distribution to occur and for the pressure 
and flow to stabilize within normal physiological limits. The infusion rate 
of All and the flow-pressure valve were adjusted empirically during the 
perfusion so as to produce a desired reduction in perfusion flow rate while 
maintaining consistent and viable kidney function. The subsequent time was 
divided into eight to ten 10-min urine collection periods for the measurement 
of kidney function and drug disposition parameters. The urine volume was 
measured with a tuberculin syringe and the pH was determined immediately. 
Perfusate (!.5 ml) was sampled at the midpoint of each urine collection. 
Isovolumetric replacement of urine loss with buffer and perfusate sampling 
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loss with blank perfusate was performed in order to minimize changes in 
perfusate composition during the experiment. 
Functionality of the rat IPK was assessed primarily by measuring glo- 
merular filtration rate (GFR), the fractional excretion of glucose (FEg~u~ose), 
and the fractional excretion of sodium (FEsodium). The renal clearance of 
inulin was taken to represent GFR. The renal clearances of chlorothiazide 
and inulin were calculated by dividing the urinary excretion rate of the 
substance by its perfusate concentration at the midpoint time interval. 
Chlorothiazide (n = 5) and control experiments (no drug present; n = 3) were 
performed in the absence and presence of AII in the perfusate. 
Analytical Methods 
Perfusate and urine samples containing chlorothiazide were analyzed 
by adopting the reversed-phase, high-performance liquid chromatographic 
assay by Lin and Benet (17). Radioactive measurements for [t4C]inulin were 
performed on an LS 3801 liquid scintillation counter (Beckman Instruments, 
Fullerton, CA) using an external standard method for quench correction. 
Glucose was determined with a YSI Model 27 Industrial Analyzer (Fisher 
Scientific, Chicago, IL) which utilizes an immobilized enzyme membrane 
mounted on the end of an electrochemical sensor, and sodium was deter- 
mined with a model 455 flame photometer (Coming Medical and Scientific, 
Medfield, MA). 
Protein Binding 
The binding of chlorothiazide to albumin in the recirculating perfusate 
was determined using 1-ml acrylic plastic dialysis cells (10). One-half milli- 
liter of perfusate was dialyzed against an equal volume of isotonic phosphate 
buffer (0.067 M, pH 7.4) in a Dubnoff Metabolic Shaking Incubator (VWR 
Scientific, Chicago, IL) at 37~ for 7 hr using Spectrapor 2 membrane tubing 
(Spectrum Medical Industries, Los Angeles, CA). Drug content in the 
dialyzed perfusate and buffer was then assayed by high-performance liquid 
chromatography, as described above. 
No evidence of nonlinear protein binding was observed in any of the 
perfusion experiments. Therefore, the percentage of unbound chlorothiazide 
in the recirculating perfusate was calculated as (18) 
100. Cf' 
% Unbound= (1) 
Cb" + Cf' 
where Cf' represents the measured unbound concentration of drug in buffer 
after dialysis, and Cb" represents the volume-corrected bound concentration 
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of drug in the postdialysis perfusate. Values for Cb" were determined using 
the following equation: 
Cb,_ Vp' . ( Cp'- Cf') (2) 
Vp 
Vp' and Vp represent the volumes of the perfusate compartment after and 
before dialysis, respectively, and Cp' represents the measured total concen- 
tration of drug in perfusate after dialysis. 
Renal Transport Model 
In general, the excretion rate of a drug from the plasma into the urine 
is expressed by 
U. V=[GFR. Ci-~ ~'~: cS]. (l-F) (3) 
Km+Cf ] 
where U is the drug concentration in urine, V is the urine flow rate, GFR is 
the glomerular filtration rate, Cfis the unbound drug concentration in per- 
fusate, Vm~x is the maximum velocity of secretion, K,. is the substrate concen- 
tration at which secretion proceeds at one-half its maximum velocity, and F 
is the fraction of filtered and secreted drug that is reabsorbed. 
If reabsorption does not occur (F= O) and the renal transport processes 
are corrected for changes in functional nephron mass, the corrected urinary 
excretion rate can be expressed by the hyperbolic model 
U" V [ (Vmax/GFR)" Cf] 
GFR = Cf+ Km+Cf (4) 
Data Analysis 
Transport data for chlorothiazide were fit to Eq. (4) using the nonlinear 
least-squares regression program MINSQ (19). The parameter estimates 
(~SD) were obtained using a weighting factor of unity. The quality of fit 
was determined by evaluating the coefficient of determination, the standard 
deviation of parameter estimates and data, and by the visual inspection of 
residuals. Statistical differences between experimental groups for the physio- 
logical or clearance parameters were determined by a two-sample t test. A 
P value_<0.05 was considered significant. 
RESULTS 
Physiological Function of the Perfused Kidney 
Control studies (no chlorothiazide) were initiated to evaluate the func- 
tional viability of the rat 1PK under normal and reduced organ perfusions 
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Table I. Effect of Angiotensin II on the Physiological Function of the Isolated 
Perfused Rat Kidney in the Absence of Chlorothiazide 
Parameter Without All a With AII b P 
Perfusion pressure (mm Hg) 80.3 4- 3.1 95.3 4- 0.6 <0.002 
Perfusate flow (ml/min) 41.84- 5.4 24.1 4-0.2 <0.005 
GFR (ml/min) 0.8074-0.171 0.7955:0.102 ns 
FE~, ...... (%) 4.304- 1.84 4.36-t- 1.28 ns 
FE~odi,:.m (%) 10.1 4- 1.6 7.274-1.66 ns 
FF (%) 1.94 4- 0.40 3.30 4- 0.44 <0.02 
Urine flow (ml/min) 0.1454-0.014 0.1094-0.015 <0.05 
Urine pH 6.334-0.085 6.335:0,000 ns 
~Data reported as the .2 + SD of three perfusion experiments in which angiotensin 
was absent from the perfusate. Each perfusion consists of ten 10-rain urine 
collection periods. 
bData reported as the .2 • SD of three perfusion experiments in which angiotensin 
was present in the perfusate (infusion rate = 1-4 ng/min). Each perfusion con- 
sists of ten 10-min urine collection periods. 
(Table I). Even though greater pressures were observed in the group contain- 
ing All, perfusate flow rate could be reduced by 42% with no change in 
GFR, FEgl . . . . . .  or FEsodiu,,,. As a result, the filtration fraction (FF) was 
increased 70%. Urine pH was stable during both treatments although urine 
flow tended to be reduced somewhat (25%) in those studies with AII present. 
Quantitatively similar trends were observed in the physiological function of 
the rat IPK when chlorothiazide was present and organ perfusion was per- 
turbed (Table II). Angiotensin induced a dramatic effect on the renal hemo- 
dynamics, resulting in a 43% reduction in perfusate flow and a 45% increase 
in filtration fraction. A small but significant decrease in GFR was observed 
Table 1I. Effect of Angiotensin II on the Physiological Function of the Isolated 
Perfused Rat Kidney in the Presence of Chlorothiazide" 
Parameter Without AII h With All '  P 
Perfusion pressure (ram Hg) 84.24-8.4 97.24-0.8 <0.01 
Perfusate flow (ml/min) 41.64-6.7 23.64-0.9 <0.001 
GFR (ml/rnin) 0.8504-0.075 0.7104-0.065 <0.02 
FEgl ...... (%) 4.18 4- 1.77 5.20 4- 1.83 ns 
FEsodlum (%) 14.8 i 2.5 15.64- 2.6 ns 
FF (%) 2.07 4- 0.26 3,00 4- 0.21 <0,001 
Urine flow (ml/min) 0.1474-0.013 0.1444-0.017 ns 
Urine pH 6.524-0.17 6.494-0.08 ns 
"Chlorothiazide was introduced to the perfusate at an initial concentration of 
100 pg/ml. 
bData reported as the .~ 4- SD of five perfusion experiments ill which angiotensin 
was absent from the perfusate. Each perfusion consists of eight to ten 10-min 
urine collection periods. 
"Data reported as the .~4- SD of five perfusion experiments in which angiotensin 
was present in the perfusate (infusion rate = 1-4 ng/min). Each perfusion con- 
sists of ten 10-rain urine collection periods. 
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(16%) with no change in FEglueose and FEsod~u,~. Urine pH and urine flow 
9 were both stable in these two experimental groups. 
Chlorothiazide Excretion 
The effect of All on the protein binding and renal clearance parameters 
of chlorothiazide are reported in Table Ill. As observed, the renal (CLr) and 
secretory (CL~) clearances were reduced by 50% under conditions of reduced 
perfusate flow (AII present). This substantial decrease could not be 
explained by alterations in protein binding since the percentage of unbound 
chlorothiazide was not different between treatments. However, small differ- 
ences in GFR could account for some of the variability in clearance param- 
eters. When the renal clearance of chlorothiazide was corrected for the 
unbound fraction (fu) and GFR, the excretion ratio (ER) was reduced by 
38% in the presence of All. Still, these comparisons assume that linear 
kinetics are obeyed. This proved not to be the case for chlorothiazide trans- 
port and, as a result, more complex models were necessary. 
Experimental data were fit to Eq. (4) to characterize the relationship 
between the corrected urinary excretion rates and unbound concentrations 
ofchlorothiazide in the rat IPK (Figs. 1 and 2). Using the input values U" V/ 
GFR and Cf, the transport parameters Vm,~/GFR and Km were obtained for 
chlorothiazide in the absence and presence of AII (Table IV). As observed, 
the V,,,,x/GFR (or Vmax) of chlorothiazide was 15-38% greater, on average, 
in the AII study group. In contrast, the Km of chlorothiazide was 133% 
greater, on average, in the presence of AII. As a result, the corrected intrinsic 
secretory clearance of chlorothiazide [( Vma~/GFR)/Km] was substantially 
reduced (41%) when the rat PIK was subjected to reduced perfusate flow. 
It should be appreciated that the reabsorption fraction, F, was assumed 
to equal zero in order to simplify the data analyses. This is a reasonable 
Table I11. Effect of Angiotensin II on the Protein Binding and Clearance 
Parameters of Chlorothiazide in the Isolated Perfused Rat Kidney 
m 
Parameter Without All" With AII b P 
Unbound (%) 6.23 + 0.43 6,04 4- 0.53 ns 
CLr (ml/min) 4.625:0.57 2.32+0.28 <0.001 
CL~ ~ (ml/min) 4.57+0.56 2.28+t:0.28 <0.001 
ER a 88.0• 54.8+7.9 < 0.001 
"Data reported as the .'~• SD of five perfusion experiments in which 
angiotensin was absent from the perfusate. Each perfusion consists of 
eight to ten 10-rain urine collection periods. 
bData reported as the s of five perfusion experiments in which 
angiotensin was present in the perfusate (infusion rate= 1-4 ng/rnin). 
Each perfusion consists of ten 10-rain urine collection periods. 
"CL~ = C L r - f u "  GFR. 
aER=CLr/ ( fu"  GFR). 
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Fig. 1. Relationship between excretion rate corrected for GFR (U. V/GFR) 
and unbound concentration (Cf) ofchlorothiazide in the rat IPK in the absence 
of All. All 48 data points from five experiments are depicted. The solid line 
represents the computer-simulated curve based on the fitted parameters of Eq. 
(4). 
assumption given the predominance of secretion in the renal elimination of 
chlorothiazide. However, if reabsorption does occur, the numerical value of 
F is probably quite similar between experiments and would not affect the 
conclusions of the study. Constancy of reabsorption (if present) is likely 
because urine flow and pH were essentially equivalent between treatment 
groups, and because the variability of these two parameters was small 
(CV< 16%) between each perfusion experiment. 
DISCUSSION 
Cardiac failure can result in a variety of pathophysiological disturb- 
ances to the kidney (4). These might include a reduced and/or  redistributed 
renal blood flow, tissue hypoxia, and visceral congestion. As a result, the 
intrinsic ability of the kidney to eliminate drug may be compromised, 
although a paucity of experimental data are available to support this correla- 
tion. For example, previous studies have reported that changes in organ 
perfusion rate may alter the renal and secretory clearances of furosemide in 
a significant manner (20-22). Although suggestive, these studies were limited 
in that renal blood flow measurements were performed in only one of the 
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Fig. 2. Relationship between excretion rate corrected for GFR (U. V/GFR) and 
unbound concentration (Cf) of chlorothiazide in the rat IPK in the presence of 
AII. All 50 data points from five experiments are depicted. The solid line repre- 
sents the computer-simulated curve based on the fitted parameters of Eq. (4). 
Table IV. Renal Transport Parameters of Chlorothiazide in the Isolated Perfused Rat Kidney" 
V,.,a~/GFR Km Vmax b ( V,.,,a~/GFR)/ 
Study group (pg/ml) (pg/ml) (pg/min) Km c r 2 d 
Chlorothiazide alone 539 (• 4.37 (• 458 (• 123 (• 0.978 
Chlorothiazide+AII 743 (• 10.2 (• 528 (• 72.8 (• 0.927 
"Data are reported as parameter estimates (• 
bvm,, was calculated as the product of V,~,ax/GFR and the mean value for GFR in each study 
group. 
c(V,,,ax/GFR)/Km was calculated as the quotient of V~,/GFR and Km in each study group. 
at2 is the coefficient of determination. 
studies. In addition, the effect of changes in protein binding as well as kidney 
functionality were not considered in the treatment of the data. There is also 
evidence to suggest that vasodilator therapy, which resulted in the improved 
renal hemodynamics of congestive heart failure patients, can increase the 
intrinsic tubular secretion of digoxin (23). In this study, both nitroprusside 
and hydralazine were able to significantly increase the digoxin renal clearance 
without changing GFR. However, these changes were inconsistent. While 
nitroprusside administration resulted in a 36% increase in digoxin CLr/GFR 
and a 36% increase in renal blood flow, hydralazine administra- 
tion resulted in only a 21% increase in digoxin CLr/GFR when renal blood 
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/ 
flow was increased by 124%. Furthermore, the use of a nonspecific radio- 
immunoassay along with a possible competition between digoxin and p- 
aminohippurate for secretory sites makes it difficult to interpret the data 
unambiguously. 
For a compound of high renal extraction (and F= 0), where the ability 
of the excretory organ to secrete the drug is much larger than the rate of 
drug delivery to the renal tubule, the secretory clearance approaches the flow 
rate (Q) of plasma perfusing the renal tubular secretion sites (1). 
CLs,~ Q (5) 
If the compound is also highly protein bound, then CLr,~ CLs, Given this 
relationship, it is obvious that changes in organ perfusion should cause 
signifcant if not proportional changes in the renal and secretory clearances 
of this compound. However, an attenuated perfusion flow rate could not 
explain the reduced clearance parameters of chlorothiazide in the present 
study since this drug is one of low renal extraction in the rat IPK (10); in 
vivo, the renal clearance of chlorothiazide approaches that of renal plasma 
flow. 
For a drug that is highly protein bound and of low renal extraction 
(and F =0), the ability of the excretory organ to secrete the drug is much 
smaller than the rate of drug delivery to the renal tubule, and 
CLr=fu 9 GFR + fu . Ks (6) 
CLr ,~ CLs =fu.  Ks (7) 
where Ks is the intrinsic renal tubular secretion clearance of unbound drug 
(equivalent to V,..x/Km). The excretion ratio (ER) can then be calculated 
by dividing the CL~ by f u .  GFR. 
Ks 
E R  = l + - -  (8) 
GFR 
Analysis of Eqs. (7) and (8) reveal that CL~ and ER should not be affected 
by changes in organ perfusion unless, as a result, the functional nephron 
mass or efficiency of tubular secretion per unit nephron, respectively, is 
altered. As shown in Table IV, it appears that the reduced intrinsic secretory 
transport of chlorothiazide reflects an inefficiency of transport (i.e., larger 
value for Kin) as opposed to a reduced number of transport sites (i.e., Vmax/ 
GFR or Vmax). Although speculative, the observed reduction in perfusion 
flow rate may have been accompanied by a redistribution of flow within the 
kidney, tisstie hypoxia, or congestion and, thereby, result in disturbed organ 
function. Alternatively, these transport changes may be the result of a direct 
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tubular effect of AII on the transporter itself. In this regard, separate experi- 
ments that can determine the direct influence of AII on tubular drug trans- 
port in the absence of a flow effect (e.g., vesicle studies) will be necessary. 
Pressure changes are an unlikely mechanism for the reduction in chlorothiaz- 
ide secretion since only a modest increase in pressure is observed in this 
treatment group (chlorothiazide + AI1). Similar reductions in secretory clear- 
ance were also observed for furosemide and cefonicid in rat IPK experiments 
in which AII caused dramatic hemodynamic changes but pressure was 
unchanged (5,24). 
In control and perfusion studies with chlorothiazide, it is evident that 
AII had no significant effects on functional nephron mass (GFR) and proxi- 
mal tubular transport per nephron (FEglucose). Although larger values are 
observed for FEsodium, as compared to FEglucose, these values are not unusual 
and probably reflect the selective damage of distal nephrons during the 
perfusion experiments (25-27). Still, the proximal tubule retains considerable 
capacity for transport, as evidenced by the relatively low and consistent 
values for FEg~ ..... in all study groups. 
A number of low perfusion flow preparations have also been described 
in the literature (28,29). Using a recirculating perfusate enriched with bovine 
erythrocytes, a significant improvement in tubular sodium handling and 
concentrating ability of the rat IPK occurs as compared to a conventional 
ceil-free medium. However, the preparations using hematocrits of 20-25% 
and 40-45% also show a GFR that is 30-40% lower than in kidneys with 
0% hematocrit, and appear to be unstable in that GFR decreases 32% on 
average over a 90-min perfusion period. More recently, kidney viability data 
were reported in a recirculating (constant pressure) and single-pass (constant 
flow) red blood cell-perfused rat kidney with hematocrits of 17% (30). In 
these recirculating perfusions, kidney function was well-maintained over a 
limited study period of 50 min and the blood perfusate flow rate was 14.4 ml/ 
rain per g kidney weight. In the present study with chlorothiazide, perfusate 
flows were approximately 17 and 30 ml/min per g kidney weight in the 
presence and absence of AII. 
Chlorothiazide is a sulfonamide diuretic that inhibits active solute trans- 
port primarily in the cortical thick ascending limb of Henle (31). As a result, 
the values for FE~od~m were increased by 62% in chlorothiazide vs. control 
perfusions with no AII (P = 0.063), and by 100% in chlorothiazide vs. control 
perfusions with AII (P<  0.002). The lack of diuretic effect in these experi- 
ments is consistent with those reported previously in the rat IPK with chloro- 
thiazide (10), and may reflect the inability to dilute/concentrate the urine in 
the distal nephron (32). Because of functional abnormalities in this tubular 
region, a word of caution is advised in studying drug dynamics in nephron 
segments beyond the proximal tubule. 
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In  summary ,  this s tudy demonstra tes  that  al terat ions in organ perfusion 
can significantly reduce the clearance parameters  of chlorothiazide in the rat  
IPK.  These flow-induced changes in intrinsic secretory t ranspor t  may reflect 
per turba t ions  other than that  of  perfusion flow rate alone. 
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